Folia Pharmacologica Japonica
Online ISSN : 1347-8397
Print ISSN : 0015-5691
ISSN-L : 0015-5691
Reviews: Corporate Challenges to Regenerative Medicine
Contribution to the world of 3D cell products created by bio 3D printing technology and to the life science field
Toshihiko Maekawa
Author information
JOURNAL RESTRICTED ACCESS FULL-TEXT HTML

2024 Volume 159 Issue 3 Pages 144-149

Details
Abstract

We have been making 3D tissues consist of cells only, based on the corporate philosophy of “contributing to dramatic advances in medical care through the practical application of innovative 3D cell stacking technology.” Currently, in the field of regenerative medicine, we are working toward obtaining approval from the Ministry of Health, Labor and Welfare and commercializing large artificial organs that are made from patients’ own cells and have functions such as nerve regeneration, osteochondral regeneration, and blood vessels. On the other hand, this three-dimensional cell stacking technology can be extended to technology for culturing cells in an environment similar to the human body, and is expected to serve as a new methodology for evaluating the effects of new products in various fields on living organisms. Therefore, we are planning a business to provide developers of pharmaceuticals, foods, cosmetics, etc. with a small device called “Functional Cell Device (FCD)” that reproduces some of the functions of human organs outside the body. As the first step, we have developed a three-dimensional liver construct (3D mini-liver). The in vitro human liver model has a wide range of usage, such as evaluation of hepatotoxicity of drugs, elucidation of drug metabolism mechanism, and model of liver disease. In this report, we will outline it together with actual examples in regenerative medicine.

Content from these authors
© 2024 by The Japanese Pharmacological Society
Previous article Next article
feedback
Top